Immunitybio announces presentation at asco gi 2023 of fully enrolled trial in third-line and greater pancreatic cancer and update on fda type b meetings regarding paths to registration

Culver city, calif.--( business wire )--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced positive results in its fully-enrolled metastatic pancreatic cancer study in third-line or greater subjects (quilt 88) showing that the overall survival rate for patients continues to be double compared to historical survival rates after two or more prior lines of therapy. the results were presented at the american society of clinical oncology gastrointestinal (asco gi) conference in san francisco january 19-21.
IBRX Ratings Summary
IBRX Quant Ranking